Braxia Scientific Corp. (BRAXF)
USD 0.0
(-9.09%)
USD 0.0
(-9.09%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 151.85 Thousand CAD | -7.69% |
| 2022 | 164.5 Thousand CAD | 179.11% |
| 2021 | 58.93 Thousand CAD | 17.96% |
| 2020 | 49.96 Thousand CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 90.98 Thousand CAD | -40.08% |
| 2024 Q3 | 528.52 Thousand CAD | 16.53% |
| 2024 Q2 | 546.32 Thousand CAD | 500.44% |
| 2023 Q4 | 151.85 Thousand CAD | -3.4% |
| 2023 FY | 151.85 Thousand CAD | -7.69% |
| 2023 Q3 | 157.19 Thousand CAD | -77.46% |
| 2023 Q2 | 697.48 Thousand CAD | 330.21% |
| 2023 Q1 | 162.12 Thousand CAD | -1.45% |
| 2022 Q4 | 164.5 Thousand CAD | 62.05% |
| 2022 FY | 164.5 Thousand CAD | 179.11% |
| 2022 Q3 | 101.51 Thousand CAD | -0.32% |
| 2022 Q2 | 101.84 Thousand CAD | -2.77% |
| 2022 Q1 | 104.75 Thousand CAD | 77.73% |
| 2021 Q1 | 49.96 Thousand CAD | 351.09% |
| 2021 Q3 | 97.65 Thousand CAD | 95.45% |
| 2021 Q2 | 49.96 Thousand CAD | 0.0% |
| 2021 FY | 58.93 Thousand CAD | 17.96% |
| 2021 Q4 | 58.93 Thousand CAD | -39.65% |
| 2020 Q4 | 11.07 Thousand CAD | 0.0% |
| 2020 Q3 | - CAD | 0.0% |
| 2020 FY | 49.96 Thousand CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.631% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 96.316% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.447% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.65% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.49% |
| Mesoblast Limited | 118.7 Million USD | 99.872% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 83.986% |
| Genus plc | 233.1 Million USD | 99.935% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 94.818% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 88.698% |
| Marizyme, Inc. | 18.71 Million USD | 99.189% |
| ContraFect Corporation | 2.88 Million USD | 94.729% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 79.753% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -12.081% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 89.501% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 93.471% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 97.316% |
| MultiCell Technologies, Inc. | 202.58 USD | -74860.509% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.736% |
| EV Biologics, Inc. | 1.49 Million USD | 89.841% |
| Q BioMed Inc. | 4.1 Million USD | 96.305% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.541% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 75.899% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 87.638% |
| Biomind Labs Inc. | 735.54 Thousand USD | 79.355% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.911% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.832% |
| Skye Bioscience, Inc. | 4.61 Million USD | 96.71% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 82.9% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -7.304% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 97.414% |
| IMV Inc. | 28.88 Million USD | 99.474% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -490.439% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 93.276% |
| GB Sciences, Inc. | 1.75 Million USD | 91.368% |
| Alpha Cognition Inc. | 1.22 Million USD | 87.557% |
| HST Global, Inc. | 98.31 Thousand USD | -54.451% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Halberd Corporation | 150 Thousand USD | -1.237% |
| Enzolytics Inc. | 996.33 Thousand USD | 84.759% |
| Resverlogix Corp. | 6.49 Million USD | 97.661% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 68.198% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 40.587% |
| argenx SE | 20 Million USD | 99.241% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.667% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 94.394% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1385.134% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.964% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 24.306% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 93.667% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 33.772% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.776% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 94.982% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 57.784% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.253% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2.153% |
| BioStem Technologies, Inc. | 4.71 Million USD | 96.777% |
| ONE Bio Corp. | 19.71 Million USD | 99.23% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 39.302% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 38.945% |
| Agentix Corp. | 50 Thousand USD | -203.71% |
| LadRx Corporation | 33.6 Thousand USD | -351.869% |
| Cell Source, Inc. | 9.25 Million USD | 98.359% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 79.919% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 79.919% |
| NovAccess Global Inc. | 2.19 Million USD | 93.097% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 97.853% |
| Itoco Inc. | 228.37 Thousand USD | 33.507% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 28.022% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 96.953% |
| Kadimastem Ltd | 891.22 Thousand USD | 82.961% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 62.211% |
| CytoDyn Inc. | 30.07 Million USD | 99.495% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 68.643% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 56.841% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 98.058% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -23.963% |
| Rebus Holdings, Inc. | 310 Thousand USD | 51.015% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 96.793% |
| International Stem Cell Corporation | 4.17 Million USD | 96.365% |
| Bioxytran, Inc. | 1.92 Million USD | 92.111% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -143.307% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 93.037% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 98.174% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 98.231% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 90.237% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 43.338% |
| Neutra Corp. | 54.15 Thousand USD | -180.403% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 91.702% |
| PureTech Health plc | 25.51 Million USD | 99.405% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 87.596% |
| IXICO plc | 472.02 Thousand USD | 67.829% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 99.02% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.756% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Cellectis S.A. | 92.77 Million USD | 99.836% |